Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1269
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 973–984 of 1,269 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting No phase listed Observational

The Vanderbilt Atrial Fibrillation Ablation Registry

NCT02404415
Site status not listed — check the official record
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
2,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Recruiting Phase 2 Interventional

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

NCT06456593
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Moderately to Severely Active Crohn Disease
Interventions
Obefazimod, Placebo
Drug · Other
Lead sponsor
Abivax S.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Sun City, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Active, not recruiting No phase listed Observational

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

NCT06107426
Site status not listed — check the official record
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
27
States / cities
Birmingham, Alabama • Sun City, Arizona • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Active, not recruiting Phase 1 Interventional

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

NCT04960579
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2042
U.S. locations
23
States / cities
Goodyear, Arizona • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Recruiting Phase 2 Interventional

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

NCT07175441
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Unresectable Hepatocellular Carcinoma
Interventions
RBS2418, STRIDE (durvalumab + tremelimumab)
Drug
Lead sponsor
Riboscience, LLC.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Nashville, Tennessee • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Active, not recruiting Not applicable Interventional

MoVE Trial: Motivational Strategies to Empower African Americans to Improve Dialysis Adherence

NCT05735743
Site status not listed — check the official record
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Motivational interviewing
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Philadelphia, Pennsylvania • Philadelphia, PA 19123, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
Status at this site: Recruiting
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

NCT05683418
Status at this site: Recruiting
View directory record Official record
Conditions
HR+/HER2-negative Breast Cancer
Interventions
TOS-358, Fulvestrant, Palbociclib, Ribociclib
Drug
Lead sponsor
Totus Medicines
Industry
Eligibility
18 Years and older · Female only
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Not yet recruiting Not applicable Interventional

Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)

NCT07355894
Site status not listed — check the official record
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
Interventions
AI-Detected CAC Notification and Care Facilitation
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 74 Years
Enrollment
120,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Pleasanton, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Recruiting Phase 1Phase 2 Interventional

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

NCT05455619
Status at this site: Recruiting
View directory record Official record
Conditions
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
Evexomostat
Drug
Lead sponsor
SynDevRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Loma Linda, California • Newport, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Recruiting Phase 2 Interventional

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

NCT05972135
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 7, 2026, 11:44 AM EST
Recruiting No phase listed Observational

EEG Abnormalities in Adult ICU Patients With High Risk of Delirium

NCT07485244
Status at this site: Recruiting
View directory record Official record
Conditions
Delirium in the Intensive Care Unit
Interventions
Ceribell EEG System
Device
Lead sponsor
Ceribell Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 7, 2026, 11:44 AM EST

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.